title: Is DOTS-plus a feasible and cost-effective strategy?
authors.affiliation: Liverpool School of Tropical Medicine, Liverpool, United Kingdom. pgarner@liv.ac.uk
authors.forename: Paul
authors.initials: P
authors.lastname: Garner
authors.forename: Marissa
authors.initials: M
authors.lastname: Alejandria
authors.forename: Mary Ann
authors.initials: MA
authors.lastname: Lansang
mesh_terms: D003362:Cost-Benefit Analysis; D023801:Directly Observed Therapy / Q000191:economics*; D005240:Feasibility Studies; D006801:Humans; D018088:Tuberculosis, Multidrug-Resistant / Q000191:economics* / Q000453:epidemiology / Q000628:therapy; D014944:World Health Organization